Referenser

  1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease. [Internet]. [uppdaterad 2023; citerad 2023‍-‍03‍-‍13].  Hämtad från: https://goldcopd.org/

  2. Adeloye D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan I; NIHR RESPIRE Global Respiratory Health Unit. Global, regional, and national prevalence of, and risk factors for, chronicobstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med. 2022 May;10(5):447‍-‍458.

  3. Backman H, Vanfleteren L, Lindberg A, Ekerljung L, Stridsman C, Axelsson M, et al. Decreased COPD prevalence in Sweden after decades of decrease in smoking. Respir Res. 2020 Oct 28;21(1):283.

  4. World Health Organization. [Internet]. Geneva: World Health Organization; [citerad 2023‍-‍03‍-‍13]. Hämtad från: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)

  5. Lamprecht B, Soriano JB, Studnicka M, Kaiser B, Vanfleteren LE, Gnatiuc L, et al; BOLD Collaborative Research Group, the EPI‍-‍SCAN Team, the PLATINO Team, and the PREPOCOL Study Group. Determinants of underdiagnosis of COPD in national and international surveys. Chest. 2015 Oct;148(4):971‍-‍985.

  6. Lindberg A, Lindberg L, Sawalha S, Nilsson U, Stridsman C, Lundbäck B, et al. Large underreporting of COPD as cause of death – results from a population based cohort study. Respir Med. 2021 Sep;186:106518.

  7. Läkemedelsverket. Behandlingsrekommendation: Kroniskt obstruktiv lungsjukdom (KOL). Uppsala, Läkemedelsverket, mars 2023.

  8. Karloh M, Fleig Mayer A, Maurici R, Pizzichini MMM, Jones PW, Pizzichini E. The COPD Assessment Test: What Do We Know So Far?: A Systematic Review and Meta-Analysis About Clinical Outcomes Prediction and Classification of Patients Into GOLD Stages. Chest. 2016;149(2):413‍-‍25. 

  9. Kocks JW, Asijee GM, Tsiligianni IG, Kerstjens HA, van der Molen T. Functional status measurement in COPD: a review of available methods and their feasibility in primary care. Prim Care Respir J. 2011;20(3):269‍-‍75.

  10. Läkemedelsverket. Vetenskapliga underlag: Kroniskt obstruktiv lungsjukdom (KOL). Uppsala, Läkemedelsverket, mars 2023.

  11. Socialstyrelsen. Nationella riktlinjer för vård vid astma och kroniskt obstruktiv lungsjukdom (KOL), 2020. [Internet] Stockholm, Socialstyrelsen. Hämtad från: https://www.socialstyrelsen.se/kunskapsstod-och-regler/regler-och-riktlinjer/nationella-riktlinjer/riktlinjer-och-utvarderingar/astma-och-kol/

  12. Spruit MA, Polkey MI, Celli B, Edwards LD, Watkins ML, Pinto‍-‍Plata V, et al. Predicting outcomes from 6‍-‍minute walk distance in chronic obstructive pulmonary disease. J Am Med Dir Assoc. 2012;13(3):291‍-‍7.

  13. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4‍-‍year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543‍-‍54.

  14. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;7:Cd009285

  15. Trivedi R, Richard N, Mehta R, Church A. Umeclidinium in patients with COPD: a randomised, placebo-controlled study. Eur Respir J. 2014;43:72‍-‍81.

  16. Ni H, Soe Z, Moe S. Aclidinium bromide for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;9:Cd010509.

  17. Wang C, Sun T, Huang Y, Humphries M, Bai L, Li L, et al. Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study. Int J Chron Obstruct Pulmon Dis. 2015;10:57‍-‍68.

  18. Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten‍-‍van Mölken MPMH, Beeh KM, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364(12):1093‍–‍103. 

  19. Decramer ML, Chapman KR, Dahl R, Frith P, Devouassoux G, Fritscher C, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med. 2013;1(7):524‍–‍33.

  20. Kew KM, Mavergames C, Walters JA. Long-acting beta‍-‍2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;10:Cd010177.

  21. Geake JB, Dabscheck EJ, Wood‍-‍Baker R, Cates CJ. Indacaterol, a once-daily beta‍-‍2-agonist, versus twice-daily beta‍-‍2-agonists or placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;1:Cd010139.

  22. Farne HA, Cates CJ. Long-acting beta‍-‍2-agonist in addition to tiotropium versus either tiotropium or long-acting beta‍-‍2-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;10:Cd008989.

  23. Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandström T, Taylor AF, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1(3):199‍–‍209. 

  24. Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta‍-‍2-agonist in one inhaler versus long-acting beta‍-‍2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD006829. 

  25. Nannini LJ, Poole P, Milan SJ, Kesterton A. Combined corticosteroid and long-acting beta‍-‍2-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013 Aug 30;2013(8):CD006826. 

  26. Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, et al; FLAME Investigators. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016 June 9;374(23):2222‍-‍34. 

  27. Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al; IMPACT Investigators. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med. 2018 May 3;378(18):1671‍-‍1680. 

  28. Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018 Mar 17;391(10125):1076‍-‍1084. 

  29. Agusti A, Fabbri LM, Singh D, Vestbo J, Celli B, Franssen FME, et al. Inhaled corticosteroids in COPD: friend or foe? Eur Resp J. 2018 Dec 13;52(6):1801‍219.

  30. Price D, Keininger DL, Viswanad B, Gasser M, Walda S, Gutzwiller FS. Factors associated with appropriate inhaler use in patients with COPD - lessons from the REAL survey. Int J Chron Obstruct Pulmon Dis. 2018‍ Feb 26;13:695‍-‍702.

  31. van der Palen J, Moeskops-van Beurden W, Dawson CM, James WY, Preece A, Midwinter D, et al. A randomized, open-label, single-visit, crossover study simulating triple-drug delivery with Ellipta compared with dual inhaler combinations in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2018 Aug 21;13:2515‍-‍2523.

  32. Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015;385:857‍-‍66.

  33. Continuous or nocturnal therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med. 1980;93:391‍-‍8.

  34. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet. 1981;1:681‍-‍6.

Föregående sida
Uppföljning

Nästa sida
Tillbaka till kapitlets första sida